I Midline sono cateteri periferici impiantati con tecnica ecoguidata, molto utili ad evitare venipunture ripetute e molto utilizzati per terapie a breve e medio termine. In questo lavoro retrospettivo multicentrico mirato a saggiare la sicurezza di tali devices, vengono presi in esame 1584 impianti effettuati in 7 anni presso alcuni centri italiani (tra cui l'ASP) e vengono riportate le complicanze, le cause di rimozione e le giornate di permanenza del catetere. Fra i 1538 pazienti adulti idonei si sono registrati 154 eventi avversi correlati al catetere pari a 2,49 eventi avversi su 1000 giorni di permanenza del midline. Si è concluso che tale catetere è considerato sicuro, affidabile, con incidenza di eventi avversi correlati, più bassa rispetto anche ai PICC. Inoltre può essere mantenuto per periodi anche molto lunghi e sicuramente maggiori di quanto avvenga oggi. c o n c i s e c o m m u n i c a t i o n
Midline catheters (MCs) may be useful to avoid repeated venipuncture in patients requiring prolonged intravenous infusions with limited adverse events (AEs). We analyzed 2 Italian hospital databases to ascertain the safety of MCs. Among 1,538 adult patients, 154 MCrelated AEs (10%; 2.49 AEs per 1,000 MC days) were reported.
Infect Control Hosp Epidemiol 2018; [1] [2] [3] When selecting the best vascular access device for a patient, the goal is always to choose the one that will best foster vessel health and preservation. 1 To improve efficiency in treatment delivery, healthcare professionals must select the most appropriate device according to the patient's needs: peripheral short catheter (PSC), extended-dwell peripheral catheter, peripherally inserted central catheter (PICC), or central venous access device (CVAD). 2, 3 Compared to PSCs, extended-dwell peripheral intravenous accesses devices, such as midline catheters (MCs) have been associated with increased dwell time and lower first-attempt failure. Moreover, the use of MCs avoids complications related to central lines, such as bloodstream infections (BSIs) and catheter-related thrombosis. 2, 3 With the increasing attention to cost control, MCs (with their longer dwell-times and low complications rates) may be a viable, cost-saving alternative to central catheters that can also ensure patient safety. In this study, we aimed to ascertain the safety of MCs.
methods
Midline-catheter data from the databases of 2 acute-care public Italian hospitals were analyzed. All inpatients and outpatients (n = 1,584) who received a MC between September 2007 to December 2014 were eligible for inclusion. We excluded those who still had the MC inserted (n = 5, 0.3%) or for whom no removal date reported (n = 41, 2.6%).
As part of standard practice, the intravenous site was prepared using an aseptic technique. Midline-catheters were inserted by a member of the MC insertion team, a team of registered nurses with a postgraduate specialization in positioning PICCs and MCs. All MCs were inserted using ultrasound-guided puncture and were 4-5 French (Fr) in diameter and 20-25 cm in length. Almost all MCs were single lumen; 4 were bilumen. After the catheter insertion, a sterile 5 × 5-cm gauze dressing was positioned and held in place with a transparent dressing, which was changed the day after insertion. Thereafter, transparent dressings were changed every 7 days. If evidence of hematic or serous leakage was noted, gauze plus transparent dressings were changed every 48 hours. Midline catheters were anchored with an adhesive-based suture-free device. After insertion, MCs were accessed by ward staff, and intravenous sites were inspected once per shift.
Midline catheters were left in situ until the end of therapy or until complications occurred, although MC manufacturers recommend a maximum dwell time of 28 days. 2 
Data Collection
Data on patient characteristics, MC characteristics, and cause of MC removal were collected. The causes of MC removal were distinguished in MC-related adverse events (eg, AEs, occlusion, exit-site infection, or symptomatic thrombosis) or other reasons (eg, accidental removal, termination of therapy, natural device expiration, or death of the patient).
The following definitions were adopted:
• Occlusion: Complete inability to flush, infuse, or aspirate; resistance with flushing and aspiration or sluggish infusion; or ability to flush and infuse but not aspirate. 4 • Exit-site infection: Presence of tenderness, erythema, and/or purulent discharge at the catheter site. 5 • Symptomatic thrombosis: Lack of flow or nonpulsatile and nonphasic flow associated with lack of compressibility of the veins, edema, and erythema of the cannulated arm. 6 Symptomatic thrombosis was confirmed by ultrasound. • Accidental removal: Unplanned removal of the catheter either by the patient or the staff. 7
Primary Outcome Measure
Midline catheter removal due to MC-related AEs was set as the primary outcome measure. Thus, the primary outcome was a composite measure defined as the number of AEs per MC days (ie, the period an MC was in place) and was presented as per 100 MCs (%) and per 1,000 MC days.
A Posteriori Sample Size Calculation
A power analysis was conducted using AE frequencies from the literature. 8 A sample of 1,538 MCs ensured an estimation of 10% of AEs with a precision of ±1.5% at a confidence level of 0.05. Each patient was included in the study only once. 
discussion
Our findings suggest that MC can be a safe device for mediumterm therapy, confirming the findings of a previous systematic review that reported that the risk of BSI was lower among patients with MCs (0.2 per 1,000 catheter days) than those with peripherally inserted central catheters (2.1 per 1, 000 catheter days) or short-term central venous catheters (2.7 per 1,000 catheter days). 3 We found a lower aggregate incidence density of all complications that those of previous reports 3, 9 ; however, we did not include pain and bleeding in the composite outcome, and we considered accidental removal separately.
The median MC dwell time (26 days) was in line with CDC guidelines, which recommend the use of a MC for intravenous therapy exceeding 6 days. 5 However, our data suggest that this ideal period could be extended up to 273 days without risk of AE occurrence. These findings confirmed a preliminary retrospective analysis of 92 home-care patients with advanced cancer, which reported a median MC dwell time of 85 days, ranging up to 1 year. 10 Thus, MCs may work successfully even beyond their recommended period of use. This consideration may be particularly important for healthcare professionals because they weigh the risk of leaving a MC in place longer than suggested against the sometimes limited benefit of more frequent replacement, especially in patients with limited life expectancy.
This study has some shortcomings. First, as with all retrospective studies, there were problems with incomplete documentation. Relevant factors that may contribute to MCrelated AEs, such as recent surgery, comorbidities (ie, obesity, diabetes, nephropathies, malnourishment), or administered drugs were not collected. Moreover, we had no information on the reason for inserting a MC or on the postinsertion use and care of the MCs. The setting of AEs (ie, inpatient or outpatient) was not specified; thus, comparisons between inpatient and outpatient AEs were not possible. We may hypothesize that the shorter dwell time in patients with an open MC or receiving supportive therapies was due to flushing practices that may need improvement (ie, positive pressure and pulsating technique), but data on the local flushing practices were not available. On the other hand, the large, heterogeneous sample makes our findings more generalizable.
In conclusion, the MC can be considered a safe device when inserted by trained nurses, with limited complications, even beyond the suggested period of use. acknowledgments Financial support: No financial support was provided relevant to this article.
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